The a2 Milk Company Limited (ACOPY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
The a2 Milk Company Limited (ACOPY) trades at $5.39 with AI Score 54/100 (Grade B). The a2 Milk Company Limited focuses on producing and selling milk and infant formula products that contain only the A2 type of beta-casein protein. Market cap: $3.91B, Sector: Consumer defensive.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for ACOPY: ACOPY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ACOPY against Consumer Defensive peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ACOPY: 4/6 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →The a2 Milk Company Limited (ACOPY) Consumer Business Overview
The a2 Milk Company Limited specializes in A2 protein milk and infant formula, differentiating itself through a focus on digestive wellness and operating across Australia, New Zealand, China, and the United States, positioning it within the consumer defensive sector with a focus on health-conscious consumers.
What Is the Investment Thesis for ACOPY?
The a2 Milk Company presents a unique investment proposition centered on its specialized A2 protein milk and infant formula products. With a current P/E ratio of 20.8 and a profit margin of 10.9%, the company demonstrates solid profitability. Key growth catalysts include further expansion in the Chinese market and increased penetration in the U.S. market. The company's strong brand recognition and focus on digestive wellness provide a competitive edge. Potential risks include regulatory changes in the infant formula market and increasing competition from established dairy players. Investors should monitor the company's ability to maintain its premium pricing and manage supply chain complexities. The dividend yield of 1.77% offers a modest return, adding to the investment case.
Based on FMP financials and quantitative analysis
ACOPY Key Highlights
- Market capitalization of $3.91B reflects investor confidence in the company's growth prospects.
- Gross margin of 46.8% indicates strong pricing power and efficient cost management.
- Profit margin of 10.9% demonstrates the company's ability to convert revenue into profit.
- Beta of 0.46 suggests lower volatility compared to the overall market.
- Dividend yield of 1.77% provides a steady income stream for investors.
Who Are ACOPY's Competitors?
ACOPY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BICEY Société BIC S.A. | $34.21 | +3.78% | $5.67B | 44 |
| CHFLF China Feihe Limited | $0.35 | +0.00% | $3.08B | 52 |
| COCSF Coca-Cola FEMSA, S.A.B. de C.V. | $10.78 | +1.41% | $5.66B | 51 |
| CUYTY Etn. Fr. Colruyt NV | $10.08 | -3.91% | $4.79B | 43 |
| GLAPY Glanbia plc | $132.77 | -3.79% | $6.42B | 48 |
| FSRCY First Resources Limited | $238.46 | +0.00% | $3.69B | 64 |
| FTROF First Resources Limited | $1.80 | -20.35% | $2.79B | 64 |
| CALM Cal-Maine Foods, Inc. | $83.98 | +0.16% | $3.98B | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACOPY's Key Strengths?
- Strong brand recognition and reputation for quality.
- Focus on a niche market with specific consumer needs.
- Established distribution network in key markets.
- Proprietary knowledge and technology related to A2 protein milk.
What Are ACOPY's Weaknesses?
- Reliance on a single product category (A2 protein milk).
- Limited geographic diversification.
- Vulnerability to changes in consumer preferences.
- Potential supply chain disruptions.
What Could Drive ACOPY Stock Higher?
- Continued expansion in the Chinese market, driven by high demand for premium infant formula.
- Increased penetration in the U.S. market, targeting health-conscious consumers.
- Potential new product launches, such as A2 protein-based dairy alternatives, in Q3 2026.
- Strategic partnerships with retailers and distributors to expand reach.
- Growing consumer awareness of the benefits of A2 protein milk.
What Are the Key Risks for ACOPY?
- Increasing competition from established dairy players in the A2 protein milk market.
- Regulatory changes in the infant formula market, particularly in China.
- Fluctuations in raw material prices, such as milk and packaging materials.
- Changes in consumer preferences and demand for A2 protein milk.
- Currency risk associated with international operations.
What Are the Growth Opportunities for ACOPY?
- Expansion in China: The Chinese market represents a significant growth opportunity for The a2 Milk Company, driven by high demand for premium infant formula and increasing disposable incomes. The company can leverage its brand recognition and distribution network to further penetrate this market. The Chinese infant formula market is estimated to be worth over $25 billion, offering substantial revenue potential. Timeline: Ongoing.
- Increased Penetration in the U.S. Market: The U.S. market offers considerable growth potential for a2 Milk, particularly among health-conscious consumers and those seeking alternatives to traditional dairy products. The company can expand its distribution channels and increase marketing efforts to raise brand awareness. The U.S. dairy alternatives market is projected to reach $45 billion by 2027. Timeline: Ongoing.
- Product Innovation: The a2 Milk Company can drive growth through product innovation, such as developing new A2 protein-based products and expanding its product line to include other dairy-related items. This can attract new customers and increase sales among existing customers. The market for innovative dairy products is growing rapidly, driven by changing consumer preferences. Timeline: Ongoing.
- Strategic Partnerships: Forming strategic partnerships with retailers and distributors can help The a2 Milk Company expand its reach and increase sales. Collaborating with key players in the dairy and infant formula industries can provide access to new markets and distribution channels. Strategic partnerships can accelerate growth and reduce costs. Timeline: Ongoing.
- Geographic Expansion: The a2 Milk Company can explore opportunities to expand into new geographic markets, such as Southeast Asia and Europe, where there is growing demand for premium dairy products. Entering new markets can diversify revenue streams and reduce reliance on existing markets. The global dairy market is expected to grow at a CAGR of 4% over the next five years. Timeline: Ongoing.
What Opportunities Does ACOPY Have?
- Expansion in China and other Asian markets.
- Increased penetration in the U.S. market.
- Product innovation and development of new A2 protein-based products.
- Strategic partnerships with retailers and distributors.
What Threats Does ACOPY Face?
- Increasing competition from established dairy players.
- Regulatory changes in the infant formula market.
- Fluctuations in raw material prices.
- Changes in consumer perceptions of A2 protein milk.
What Are ACOPY's Competitive Advantages?
- Brand recognition and reputation for quality.
- Proprietary knowledge and technology related to A2 protein milk.
- Established distribution network in key markets.
- Focus on a niche market with specific consumer needs.
What Does ACOPY Do?
The a2 Milk Company Limited was founded in 2000 in Auckland, New Zealand, with the aim of commercializing milk products containing only the A2 type of beta-casein protein. The company's core innovation lies in identifying and segregating cows that naturally produce milk without the A1 beta-casein protein, which some studies suggest can cause digestive discomfort in certain individuals. This led to the development of the a2 Milk brand, which is now the company's flagship product. Over the years, a2 Milk has expanded its product line to include infant formula under the a2 Platinum brand, catering to the growing demand for premium infant nutrition. The company has strategically expanded its geographic footprint, establishing a significant presence in Australia and New Zealand, and aggressively targeting the Chinese market, where demand for high-quality infant formula is substantial. It also operates in the United States, focusing on health-conscious consumers. The a2 Milk Company differentiates itself through its focus on A2 protein milk and related products, positioning itself as a premium brand in the consumer defensive sector.
What Products and Services Does ACOPY Offer?
- Sells fresh milk under the a2 Milk brand.
- Offers infant formula under the a2 Platinum brand.
- Focuses on products containing only the A2 type of beta-casein protein.
- Markets its products in Australia, New Zealand, China, and the United States.
- Targets health-conscious consumers and those seeking digestive wellness.
- Differentiates itself through its focus on A2 protein milk.
How Does ACOPY Make Money?
- Produces and sells A2 protein type branded milk.
- Generates revenue from the sale of fresh milk and infant formula.
- Focuses on premium pricing and brand differentiation.
- Utilizes a distribution network to reach consumers in key markets.
What Industry Does ACOPY Operate In?
The a2 Milk Company operates within the agricultural farm products industry, a segment of the broader consumer defensive sector. The industry is characterized by stable demand, as food and beverage products are essential consumer needs. The global dairy market is highly competitive, with major players such as BICEY (Danone), CHFLF (Nestle), COCSF (Fonterra), CUYTY (Unilever), and GLAPY (Lactalis) vying for market share. The a2 Milk Company differentiates itself by focusing on A2 protein milk, catering to consumers seeking digestive wellness. The market for infant formula is particularly lucrative, driven by increasing birth rates in developing countries and growing awareness of premium nutrition.
Who Are ACOPY's Key Customers?
- Health-conscious consumers seeking digestive wellness.
- Parents looking for premium infant formula.
- Retail consumers in Australia, New Zealand, China, and the United States.
- Consumers seeking alternatives to traditional dairy products.
Company Profile
The a2 Milk Company Limited operates in the Agricultural Farm Products industry within the Consumer Defensive sector. It is headquartered in Auckland, NZ. The company is led by CEO David L. Bortolussi. ACOPY has traded publicly since 2019.
ROE 16%Key Financial Metrics
Return on equity for The a2 Milk Company Limited stands at 15.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 12.2%, showing how much profit it generates from its asset base. ACOPY trades at a trailing price-to-earnings ratio of 20.76, below the Consumer Defensive sector average of ~29x. Its free cash flow yield is 4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.8%, the inverse of the P/E and a quick read on earnings relative to price.
ACOPY Valuation & Market Position
With a $3.91B market cap, The a2 Milk Company Limited sits in the mid-cap segment of the market. Relative to its peer group, ACOPY's quantitative score of 54/100 is roughly in line with the peer average of 48/100.
Quarterly Financial Performance: The a2 Milk Company Limited
Revenue for The a2 Milk Company Limited came in at $1.01B during Q4 2025. The company recorded net income of $115.4M, with diluted EPS of $0.16. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Consumer Defensive. Across the four most recent quarters, ACOPY averaged $0.12 in diluted EPS.
F-Score 7/9Financial Health
The a2 Milk Company Limited's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 12.42 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project The a2 Milk Company Limited revenue of about $1.98B for fiscal 2026, with EPS near $0.00. The estimate reflects 13 contributing analysts.
ACOPY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in its growth potential.
- Community sentiment has shifted positively, with discussions highlighting the brand's strong market position and product quality.
- The company's expansion into new markets has been well-received, with social media buzz reflecting excitement about its growth strategy.
- Recent product innovations have sparked interest, leading to increased consumer engagement and positive feedback on social platforms.
Bear Case
- Concerns about inflationary pressures affecting consumer spending could impact sales, as some community members express caution regarding discretionary spending.
- Recent reports indicate increased competition in the dairy sector, raising worries about market share erosion and pricing pressures.
- Community sentiment has shown some skepticism regarding the sustainability of recent growth, with discussions reflecting doubts about long-term demand.
- Negative commentary around supply chain challenges persists, with traders worried about potential disruptions affecting product availability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.01B | $115M | $0.16 |
| Q2 2025 | $1.01B | $111M | $0.15 |
| Q4 2024 | $893M | $92M | $0.13 |
| Q2 2024 | $431M | $41M | $0.06 |
Based on FMP financials and quantitative analysis
ACOPY Latest News
-
a2 Milk Recall Puts Infant Formula Trust And US Growth Under Review
Yahoo! Finance: ACOPY News · May 8, 2026
ACOPY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACOPY.
Price Targets
Wall Street price target analysis for ACOPY.
ACOPY MoonshotScore
What does this score mean?
The MoonshotScore rates ACOPY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Agricultural Farm ProductsLeadership: David L. Bortolussi
CEO
David L. Bortolussi serves as the CEO of The a2 Milk Company Limited, overseeing the company's global operations and strategic direction. His career spans various leadership roles in the consumer goods industry, bringing extensive experience in brand management, marketing, and international expansion. Before joining The a2 Milk Company, Bortolussi held senior positions at prominent multinational corporations, where he led successful product launches and market development initiatives. He is known for his strategic vision and ability to drive growth in competitive markets.
Track Record: Under David L. Bortolussi's leadership, The a2 Milk Company has continued to expand its presence in key markets such as China and the United States. He has focused on strengthening the company's brand recognition and improving its supply chain efficiency. Bortolussi has also overseen the development of new product offerings and the implementation of innovative marketing strategies. His tenure has been marked by a commitment to sustainable growth and shareholder value.
The a2 Milk Company Limited ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For ACOPY, each ADR represents a certain number of shares of The a2 Milk Company Limited traded on its home market. This allows U.S. investors to easily invest in ACOPY without dealing with foreign exchanges.
- Home Market Ticker: New Zealand Stock Exchange (NZX), Auckland, New Zealand
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: ACOP
ACOPY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier typically have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for price manipulation and fraud.
- Higher risk of illiquidity and price volatility.
- Lack of regulatory oversight and investor protection.
- Uncertainty regarding the company's financial condition and future prospects.
- Verify the company's registration and legal status.
- Review the company's financial statements, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Consult with a financial advisor and conduct thorough research.
- Understand the risks associated with investing in OTC stocks.
- Established presence in key markets (Australia, New Zealand, China, United States).
- Focus on a niche market with specific consumer needs (A2 protein milk).
- Brand recognition and reputation for quality.
- Continued operations since incorporation in 2000.
- Presence of a CEO and management team.
Common Questions About ACOPY (Consumer Defensive)
What does The a2 Milk Company Limited do?
The a2 Milk Company Limited specializes in producing and selling milk and infant formula products that contain only the A2 type of beta-casein protein. Its flagship product, a2 Milk, caters to consumers seeking digestive wellness by offering milk free from the A1 beta-casein protein, which some studies suggest can cause discomfort. The company also offers a2 Platinum infant formula. The a2 Milk Company operates in key markets including Australia, New Zealand, China, and the United States, focusing on health-conscious consumers and parents seeking premium infant nutrition.
What are the main risks for ACOPY?
The main risks for The a2 Milk Company Limited include increasing competition from established dairy players, regulatory changes in the infant formula market (particularly in China), fluctuations in raw material prices, and changes in consumer preferences. As an ADR trading on the OTC market, ACOPY also faces risks related to limited financial disclosure, potential price volatility, and currency fluctuations. Investors should carefully consider these risks before investing in ACOPY.
What are the key factors to evaluate for ACOPY?
The a2 Milk Company Limited (ACOPY) holds an AI score of 54/100 (moderate). P/E: 20.8x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does ACOPY data refresh on this page?
ACOPY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ACOPY's recent stock price performance?
The a2 Milk Company Limited (ACOPY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand recognition and reputation for quality. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACOPY overvalued or undervalued right now?
The a2 Milk Company Limited (ACOPY) trades at 20.8x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ACOPY?
Before investing in The a2 Milk Company Limited (ACOPY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ACOPY to a portfolio?
Key strength of The a2 Milk Company Limited (ACOPY): Strong brand recognition and reputation for quality. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.
- Disclosure status on OTC markets is unknown.